By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 131.95 |
Change Today | $ 3.95 |
% Change | 3.09 % |
52 Week High | $214.63 |
52 Week Low | $118.84 |
Volume | 2,798,550 |
Shares Issued | 145.80m |
Market Cap | $19,238m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 8 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 196,540 @ $131.95 |
15:59 | 100 @ $131.97 |
15:59 | 158 @ $131.94 |
15:59 | 103 @ $131.94 |
15:59 | 593 @ $131.90 |
You are here: research